NCT06633419View on ClinicalTrials.gov

A Drug-Drug Interaction Study of Carbamazepine and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-012)

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

December 18, 2024

Primary Completion Date

February 12, 2025

Study Completion Date

May 13, 2025

Conditions
Healthy
Interventions
DRUG

Opevesostat

Administered via oral tablet per dosing regimen.

DRUG

Prednisone

Administered at a dose of 5 mg or 10 mg dependent on HRT dosing regimen via oral tablets.

DRUG

Fludrocortisone acetate

Administered at a dose of 0.05 mg or 0.1 mg dependent on HRT dosing regimen via oral tablets.

DRUG

Carbamazepine

Administered at a dose of 100 mg, 200 mg, or 300 mg BID dependent on dosing regimen via oral capsule (extended-release).

Trial Locations (1)

85283

Celerion ( Site 0001), Tempe

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT06633419 - A Drug-Drug Interaction Study of Carbamazepine and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-012) | Biotech Hunter | Biotech Hunter